AWCI
ALT icon

Alpine Woods Capital Investors’s Altimmune ALT Stock Holding History

Alpine Woods Capital Investors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,383
Closed -$1.35M – 452
2016
Q4 		$1.35M Buy
+1,383
New +$1.24M 0.07% 207

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Alpine Woods Capital Investors's ALT Position: Q1 2017 in Review

Alpine Woods Capital Investors sold out of Altimmune (ALT) in Q1 2017, closing a stake of 1,383 shares — an estimated $1.35M sold.

Alpine Woods Capital Investors first reported a position in ALT in Q4 2016 and held it in 1 quarter. The position peaked at $1.35M in Q4 2016. 71 funds tracked by Wall St. Rank hold ALT as of Q1 2017.

  • Alpine Woods Capital Investors reported no remaining Altimmune position as of Q1 2017 after selling out during the quarter.
  • Alpine Woods Capital Investors sold 1,383 Altimmune shares in Q1 2017, an estimated $1.35M.
  • Alpine Woods Capital Investors first reported a position in Altimmune in Q4 2016 and held it in 1 quarter.
  • Alpine Woods Capital Investors's Altimmune position peaked at $1.35M in Q4 2016.
  • 71 funds tracked by Wall St. Rank held Altimmune as of Q1 2017.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2017, filed 3 May 2017.